Eyes On Eyecare

Sight Sciences, Inc. is introducing a new addition to its OMNI product line: the OMNI Edge Surgical System for minimally invasive glaucoma surgery (MIGS). The system’s unveiling coincides with the 2025 annual meeting of the American Society of Cataract and Refractive Surgery (ASCRS), April 25-27, in Los Angeles, California. Learn more on Glance: https://hubs.ly/Q03jXnd_0 #GlanceNews #eyecare Rigo Magaña

Don't miss largest FREE virtual glaucoma-focused event of the year! At Eyes On Glaucoma, world-class OD and MD speakers will share insights on key glaucoma strategies, imaging techniques, and more. Get the latest on surgical options and interventional glaucoma practice patterns, and take advantage of the opportunity to earn up to 4.5 credits of CE through 6 COPE-accredited sessions!   Save your seat today: https://hubs.ly/Q03htVGJ0

Just weeks after initiating a voluntary recall of select intraocular lenses (IOLs), Bausch + Lomb Corporation announced those lenses will now return to market. Learn more on Glance: https://hubs.ly/Q03jMLYp0 #GlanceNews #eyecare

Discover the latest clinical pearls and research about autologous serum eye drops from experts Nandini Venkateswaran, MD, and Vin T. Dang, OD, FAAO. Learn how to access serum, spot ideal candidates, and set realistic expectations. Get started here: https://hubs.ly/Q03h8mvv0

TearRestore, Inc. is introducing a new addition to its portfolio of over-the-counter (OTC) eyecare products: the WINQ Eyelid Serum. Learn more on Glance: https://lnkd.in/eEyJkhxm #GlanceNews #eyecare Ken DauSchmidt

BVI Medical has received 510(k) clearance from the FDA for its next-generation laser endoscopy ophthalmic system, dubbed “Leos.” Learn more on Glance: https://hubs.ly/Q03hXFWX0 #GlanceNews #FDA Aimee Shimamoto

Just shy of 1 year since the FDA approved Biocon Biologics Limited’s YESAFILI (aflibercept-jbvf) as an interchangeable biosimilar for Regeneron Pharmaceuticals, Inc.’s EYLEA, the two companies have agreed to a settlement and license agreement. What this means: Biocon is now cleared to launch its generic drug in the United States. Learn more on Glance: https://hubs.ly/Q03hV4BC0 #GlanceNews #eyecare Shreehas Tambe

Pykus Therapeutics, Inc. announced the completion of participant enrollment for a pilot study evaluating the use of PYK-2101, a retinal sealant, in patients receiving vitreoretinal surgery. Learn more on Glance: https://hubs.ly/Q03hG0yw0 #GlanceNews #eyecare James (Tony) Stefater

Is semaglutide really tied to a rise in non-arteritic anterior ischemic optic neuropathy—or is there more to the story? Find the anwers and more with John W Kitchens, MD, and Ehsan Rahimy, MD, as they break it all down: the data, the outliers, and how EHR is helping retina specialists connect the dots faster than ever. Get started: https://hubs.ly/Q03htwSK0

Opus Genetics, Inc. released pediatric clinical findings from its first-in-human (FIH) phase 1/2 study evaluating the OPGx-LCA5, an investigational ocular gene therapy, for the treatment of patients diagnosed with Leber congenital amaurosis (LCA) resulting from biallelic mutations in the LCA5 gene. Learn more on Glance: https://hubs.ly/Q03h0H3W0 #GlanceNews #eyecare Susan Benton